Journal
Frontiers in Oncology
Publication Date
1-1-2024
Volume
14
First Page
1483953
Document Type
Open Access Publication
DOI
10.3389/fonc.2024.1483953
Rights and Permissions
Hansen AR, Probst S, Beauregard J-M, Viglianti BL, Michalski JM, Tagawa ST, Sartor O, Tutrone RF, Oz OK, Courtney KD, Delpassand ES, Nordquist LT, Osman MM, Chi KN, Sparks R, George N, Hawley SM, Wu W, Jensen JD and Fleshner NE (2025) Initial clinical experience with [177Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial. Front. Oncol. 14:1483953. doi: 10.3389/fonc.2024.1483953 © 2025 Hansen, Probst, Beauregard, Viglianti, Michalski, Tagawa, Sartor, Tutrone, Oz, Courtney, Delpassand, Nordquist, Osman, Chi, Sparks, George, Hawley, Wu, Jensen and Fleshner. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Recommended Citation
Hansen, Aaron R; Michalski, Jeff M; and et al., "Initial clinical experience with [177Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: Dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial." Frontiers in Oncology. 14, 1483953 (2024).
https://digitalcommons.wustl.edu/oa_4/7540
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
